Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab
Witzig, T.E.; Inwards, D.J.; Habermann, T.M.; Dogan, A.; Kurtin, P.J.; Gross, J.B.; Ananthamurthy, A.; Ristow, K.M.; Garity, J.A.
Mayo Clinic Proceedings 82(6): 692-699
2007
ISSN/ISBN: 0025-6196 PMID: 17550749 Document Number: 608764
Objective: to report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab.Patients and Methods: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab.Results: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphorna were treated with rituximab, 375 mg/m(2), intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab.Conclusion: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.